Tourlite Capital Q1 2024 Investor Letter

Tourlite Capital Management, LP is an asset management firm focused on long/short equity investing in public companies. Tourlite Fund, LP returned 6.0% for the First Quarter of 2024. The Fund has annualized returns of 10.0%, compared to the S&P 500 and Russell 2000.

3 Potential Biopharma Buyout Targets

Recent lack of M&A activity and rising interest rates have led to a 20% decline in small-cap biotech equities. Big Pharma's surplus of cash and key patent expirations should lead to increased M& a volume in the coming year. Three promising small biopharma names are attractive as standalone entities but would make logical buyout targets. Mirum Pharmaceuticals, Inc., ImmunoGen, Inc. And GLP-1 are three names that could be attractive.

Is SPDR S&P Biotech ETF (XBI) a Strong ETF Right Now?

Weekly Report: what happened at XBI last week (0415-0419)?

Some Bubbles Are Starting To Pop

The S&P 500 posted its worst weekly performance since March of 2023 this week. The yield on the 10-Year Treasury has risen to 4.62% from 3.9% in late February. Bubbles in the AI sector and high beta parts of the market are deflating. Rising interest rates are also impacting the commercial real estate sector.

XBI: 3 Reasons To Buy The Pullback And Hold This Biotech ETF Forever

Noteworthy ETF Outflows: XBI, ALPN, RVMD, EXAS

XBI Crowded With Sellers

Weekly Report: what happened at XBI last week (0408-0412)?

Should You Invest in the VanEck Biotech ETF (BBH)?

Thursday's ETF Movers: XBI, KIE

Top 10 best performing S&P 500 health care stocks of 2024

19 of the 65 health care stocks within the S&P 500 have topped the broader market's performance in 2024. The health care sector traditionally has been seen as a defensive sector. The top 10 best performing health care companies in 2024 are all in the Health Care sector.

Noteworthy ETF Outflows: XBI, EXAS, CRNX, CYTK

Is First Trust NYSE Arca Biotechnology ETF (FBT) a Strong ETF Right Now?

Weekly Report: what happened at XBI last week (0401-0405)?

Morgan Stanley sees Fed rate cut fueling biotech stock performance

Morgan Stanley sees Fed rate cut fueling biotech stocks. The bank expects to see the first rate cut in June. Lower rates have historically coincided with an uptick in M&A activity in the biotech sector. Morgan Stanley sees oncology and immunology assets continuing to attract interest.

Is iShares Biotechnology ETF (IBB) a Strong ETF Right Now?

Clean Energy, Semiconductors Among Interest-Rate-Sensitive Sectors Hammered Thursday Afternoon On Rate Cut Concerns

U.S. Labor Department reports more initial jobless claims than expected. All indices opened the day higher. But Fed speakers appeared tentative about the notion of cutting interest rates too early, sending stocks into a freefall. The data was construed as a signal the labor market is cooling down.

Zacks Investment Ideas feature highlights: SPDR S&P Biotech ETF, iShares Biotech ETF, Viking Therapeutics and Madrigal Pharmaceuticals

Weekly Report: what happened at XBI last week (0325-0329)?